Sigachi Industries has received disclosure from its promoter RPS Industries Private Limited regarding the invocation of pledged equity shares under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The disclosure, dated 29.01.2026, details the invocation of 1,15,03,000 pledged equity shares across multiple transactions in January 2026.

Pledge Invocation Details

The invocation of pledged shares occurred across three separate dates with different beneficiaries:

The largest single invocation involved 1,00,00,000 shares transferred to Anurag Reddy on 14.01.2026, while the remaining shares were invoked in favor of IIFL Securities Ltd across two separate dates.

Current Shareholding Position

Following the pledge invocations, RPS Industries Private Limited's shareholding structure in Sigachi Industries has been updated:

Regulatory Compliance

The disclosure was made in accordance with Regulation 31(3) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. RPS Industries Private Limited, through Director Swati Sinha (DIN: 08097594), submitted the required documentation to both BSE Limited and National Stock Exchange of India Limited on 29.01.2026.

The invocation represents a significant reduction in the encumbered shareholding of the promoter entity, decreasing the pledged portion from 15.53% to 12.52% of Sigachi Industries' total share capital. Despite the pledge invocations, RPS Industries maintains its overall shareholding of 17.76% in the target company.

Sigachi Industries has achieved a significant research and development milestone in the field of cystic fibrosis Active Pharmaceutical Ingredients (APIs). This breakthrough represents a major advancement in the company's pharmaceutical development capabilities and positions it strategically in the specialized therapeutic market.

R&D Milestone Achievement

The company has successfully reached an important R&D goal specifically related to cystic fibrosis APIs. This achievement demonstrates Sigachi Industries' commitment to developing specialized pharmaceutical ingredients for rare and complex medical conditions. Cystic fibrosis APIs represent a niche but valuable segment within the pharmaceutical industry, requiring specialized expertise and advanced manufacturing capabilities.

Revenue Projections

The successful completion of this R&D milestone is expected to translate into substantial revenue generation for the company. The following table outlines the anticipated financial impact:

Strategic Implications

This R&D achievement positions Sigachi Industries to enter a specialized pharmaceutical market segment. The development of cystic fibrosis APIs represents the company's expansion into complex therapeutic areas, potentially enhancing its product portfolio and market positioning. The expected revenue generation starting from Q4 of FY 2026-27 indicates a clear commercialization timeline for this research breakthrough.

The milestone reflects the company's investment in research and development capabilities, particularly in addressing rare disease treatments. This achievement could establish Sigachi Industries as a key player in the specialized API manufacturing sector for cystic fibrosis therapeutics.